Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch

Core Insights - In 2025, Insmed (INSM) experienced significant stock growth, more than doubling in value from January to December, outperforming both the biotech sector and the broader market [1] Company Overview - Insmed gained investor attention following a key approval, which contributed to its stock performance [1] Leadership Background - The company has a co-founder, Brendan, who has a strong academic and professional background, including a Ph.D. from Stanford University and experience at major pharmaceutical and biotech firms [1]